On Friday, Haleon ADR cleared an important performance benchmark, with its Relative Strength (RS) Rating entering into the 80-plus percentile with an improvement to 83, a rise from 79 the day before.
This proprietary rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks matches up against other publicly traded companies.
History shows that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating as they launch their biggest runs.
Risk Management In The Stock Market: How Much Money To Invest Now
Haleon ADR is building a cup with handle with a 10.79 entry. See if the stock can clear the breakout price in volume at least 40% higher than normal.
Haleon ADR reported negative growth for both the top and bottom lines last quarter.
The company earns the No. 4 rank among its peers in the Medical-Generic Drugs industry group. ANI Pharmaceuticals is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
